Ovarian and Fallopian Tube Cancer Risk Management
Stay up to date on research and information
Sign Up for FORCE NewslettersOvarian and Fallopian Tube Cancer Risk Management
Every woman is at risk for ovarian and fallopian tube cancer and the risk increases with age. The average lifetime risk for these cancers is slightly more than 1 percent. About 1 out of every 90 women will get ovarian or fallopian tube cancer in her lifetime. Note that when we use "women" we are referring to the sex assigned at birth.
An inherited mutation in one of the genes listed below increases the risk for these cancers, often at a younger age.
Genetic counseling and testing can help you learn if you have an inherited mutation in one of these genes. There are different expert guidelines for ovarian and fallopian tube cancer risk management, which are based on your level of risk. Read below for more information about different risk-management options. Speak with your healthcare provider to decide on a risk-management plan and schedule that is right for you.
In the News
Topic : Reducing ovarian cancer risk without removing the ovaries
A leading ovarian cancer organization has recommended that all women who have pelvic surgery should also consider removing their fallopian tubes to reduce their risk of ovarian cancer. (Posted 7/18/23)
Risk-Management Options
Screening
Screening for ovarian and fallopian tube cancer uses tests to try to catch cancer in its early stages. In high-risk people, regular screening for these cancers may not improve outcomes. Learn more about the benefits and limitations of fallopian tube and ovarian cancer screening.
Medications to Reduce Risk
Medications such as birth control pills can lower the risk for fallopian tube and ovarian cancer in people with inherited mutations. Learn more about the benefits and risks of these medications.
Surgery to Reduce Risk
Risk-reducing surgery is the most effective way to lower risk for ovarian and fallopian tube cancer. Read more about the guidelines and surgery options for people with inherited mutations.
Participate in Ovarian Cancer Prevention Research
Clinicaltrials.gov identifier:
NCT04251052
Clinicaltrials.gov identifier:
NCT05287451
Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation
Clinicaltrials.gov identifier:
NCT04367675
Clinicaltrials.gov identifier:
NCT05677048
Developing a Test for the Detection of Ovarian Cancer
Clinicaltrials.gov identifier:
NCT04794322
